Results 31 to 40 of about 1,000,209 (254)

Is hepatitis delta underestimated?

Liver international (Print), 2021
Hepatitis D virus may be underestimated because it is a significant problem in HBsAg‐positive patients, especially those who inject drugs, have HIV or HCV co‐infections and/or live in certain endemic regions.
M. Papatheodoridi, G. Papatheodoridis
semanticscholar   +1 more source

Chronic viral hepatitis D - the current state of a problem. [PDF]

Ķazaķstannyṇ Klinikalyķ Medicinasy, 2017
Chronic hepatitis D- severe and rapidly progressing form of viral hepatitis, leading to the liver cirrhosis in 70% of cases within 5-10 years. HDV RNA replicates only in the presence of viral hepatitis B.
Aliya Konysbekova
doaj   +1 more source

A Case Report of Hepatocellular Carcinoma 5 Years After HBsAg Loss in Chronic Hepatitis Delta: How Long Surveillance is Required?

Annals of Hepatology, 2017
Background: Hepatitis delta virus infection occurs as acute coinfection or as superinfection in patients with preexisting chronic hepatitis B. Chronic hepatitis delta leads to more severe disease than chronic hepatitis B, with more rapid progression of ...
Laura Escolà-Vergé, Mar Riveiro-Barciela, Maria Buti   +2 more
doaj   +1 more source

Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

JHEP Reports, 2023
Summary Chronic infection with hepatitis delta virus (HDV) affects between 12-20 million people worldwide and represents the most severe form of viral hepatitis, leading to accelerated liver disease progression, cirrhosis and its complications, such as ...
P. Lampertico, E. Degasperi, L. Sandmann, Heiner Wedemeyer, C. Yurdaydın, D. Roulot, F. Zoulim, F. Căruntu, H. Kefalakes, J. Lucifora, K. Agarwal, L. Castéra, M. Buti, M. Rizzetto, M. Cornberg, M. Dandri, M. Brunetto, N. Reau, P. Lampertico, R. Gish, S. Hamid, S. Aleman, S. Urban, T. Asselah, T. Berg, V. de Lédinghen   +25 more
semanticscholar   +1 more source

Hepatitis Delta Infections in Toronto, Ontario

Canadian Journal of Gastroenterology, 1988
This study assessed the prevalence of hepatitis delta virus infection, the relation of this infection to the clinical and histological status and to the geographic origin of 216 patients with hepatitis B virus infection in Toronto, Ontario.
S. Victor Feinman, Barnet Berris, John L. Gerin, Robert H. Purcell   +3 more
doaj   +1 more source

Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection

Journal of Infectious Diseases, 2019
Background Hepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact global disease burden remains largely obscure.
Zhijiang Miao, Shaoshi Zhang, X. Ou, Shan Li, Zhongren Ma, Wenshi Wang, M. Peppelenbosch, Jiaye Liu, Q. Pan   +8 more
semanticscholar   +1 more source

Estimation of the Secondary Attack Rate for Delta Hepatitis Coinfection among Injection Drug Users

Canadian Journal of Infectious Diseases, 1993
The secondary attack rate for delta hepatitis coinfection was estimated among a cluster of injection drug users (IDUs). The infections occurred during an epidemic of hepatitis B in a rural area of Nova Scotia in 1988 and 1989.
Christiane Poulin, Theresa Gyorkos, Lawrence Joseph   +2 more
doaj   +1 more source

A review on hepatitis D: From virology to new therapies

Journal of Advanced Research, 2019
Hepatitis delta virus (HDV) is a defective virus that requires the hepatitis B virus (HBV) to complete its life cycle in human hepatocytes. HDV virions contain an envelope incorporating HBV surface antigen protein and a ribonucleoprotein containing the ...
Nathalie Mentha, Sophie Clément, Francesco Negro, Dulce Alfaiate   +3 more
doaj   +1 more source

Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta

Journal of Viral Hepatitis, 2020
Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. PEG‐interferon alpha‐2a (PEG‐IFNα‐2a) is the only effective treatment but its long‐term clinical impact is unclear.
A. Wranke, S. Hardtke, B. Heidrich, G. Dalekos, K. Yalcin, F. Tabak, S. Gurel, Y. Çakaloğlu, U. Akarca, F. Lammert, D. Häussinger, T. Müller, M. Wöbse, M. Manns, R. Idilman, M. Cornberg, H. Wedemeyer, C. Yurdaydın   +17 more
semanticscholar   +1 more source

Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139‐Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection

Hepatology Communications, 2020
The nucleic acid polymer REP 2139 inhibits assembly/secretion of hepatitis B virus (HBV) subviral particles. Previously, REP 2139‐Ca and pegylated interferon (pegIFN) in HBV/hepatitis delta virus (HDV) coinfection achieved high rates of HDV RNA and ...
M. Bazinet, V. Pantea, V. Cebotarescu, Lilia Cojuhari, P. Jimbei, Mark Anderson, Jeffrey Gersch, V. Holzmayer, C. Elsner, A. Krawczyk, M. Kuhns, G. Cloherty, U. Dittmer, A. Vaillant   +13 more
semanticscholar   +1 more source